Artificial intelligence-based approaches for improving regulatory market access – a case study with a scoping review for repurposing of medicinal products in the pandemic
DOI:
https://doi.org/10.2478/AMB-2026-0026Keywords:
AI, drug development, market access, drug repurposingAbstract
Abstract. Artificial Intelligence (AI) has already proven its impact on medical practice and science. With the increasing generation of healthcare data, AI applications offer enormous potential in clinical and regulatory decision-making, public health and administration, as well as in research and development. We conducted a scoping literature review to identify publications that discuss potential AI-based technologies for identifying repurposing-eligible medicines and for improving access to innovative therapies. More than half of the articles (18/26, 69%) were published in 2020 and 2021, during the peak of the COVID-19 pandemic, and focused on developing AI-based algorithms to accelerate screening for medicines that could be potentially repurposed. These algorithms proved to be a powerful tool to save resources and time during the pandemic, fulfil unmet medical needs and facilitate faster access to innovations. Most articles aimed to provide the scientific community and researchers with a strong rationale and/or support for the application of AI-based tools in the process of drug repurposing. However, more studies need to be performed, as currently, AI-based tools for drug repurposing need further verification.
References
Paras MA, Pathania M, Kumar, et al. Overview of artificial intelligence in medicine. J Family Med Prim Care. (2019) 8:2328–31. doi: 10.4103/jfmpc.jfmpc_440_19
Hamet P, Tremblay J. Artificial intelligence in medicine. Metabolism. 2017 Apr; 69S:S36-S40. doi: 10.1016/j.metabol.2017.01.011
Kokudeva M, Vichev M, Naseva E, et al. Artificial intelligence as a tool in drug discovery and development. World J Exp Med. 2024 Sep 20;14(3):96042. doi: 10.5493/wjem.v14.i3.96042
Toshev A, Petkova-Gueorguieva E, Mihaylova AA, et al. Digitalization of health care and aspects of implementing electronic prescriptions in Bulgaria. Pharmacia. 2024,71: 1-6. https://doi.org/10.3897/pharmacia.71.e130302
Alami H, Lehoux P, Auclair Y, et al. Artificial Intelligence and Health Technology Assessment: Anticipating a New Level of Complexity. J Med Internet Res. 2020 Jul 7;22(7):e17707. doi: 10.2196/17707.
Gancheva V, Lazarova M, Vetova S, et al. Application of Artificial Intelligence Techniques in Healthcare Data Analytics. In: Rojas I, Ortuño F, Rojas F, et al. (eds) Bioinformatics and Biomedical Engineering. IWBBIO 2024. Lecture Notes in Computer Science, vol 14848. Springer, Cham. https://doi.org/10.1007/978-3-031-64629-4_25
Hodos RA, Kidd BA, Shameer K, et al. In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med. 2016;8(3):186–210.
Paik H, Chen B, Sirota M, et al. Integrating clinical phenotype and gene expression data to prioritize novel drug uses. CPT Pharmacometrics Syst Pharmacol 5. 2016; (11):599–607.
Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010; 9(3):203–214.
Caskey CT. The drug development crisis: efficiency and safety. Annu Rev Med. 2007;58:1-16. doi: 10.1146/annurev.med.58.042705.124037.
Paul D, Sanap G, Shenoy S, et al. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26(1):80-93. doi: 10.1016/j.drudis.2020.10.010
Blanco-González A, Cabezón A, Seco-González A, et al. The Role of AI in Drug Discovery: Challenges, Opportunities, and Strategies. Pharmaceuticals (Basel). 2023 Jun 18;16(6):891. doi: 10.3390/ph16060891
Massalha S, Clarkin O, Thornhill R, et al. Decision Support Tools, Systems, and Artificial Intelligence in Cardiac Imaging. Can J Cardiol. 2018 Jul;34(7):827-838. doi: 10.1016/j.cjca.2018.04.032.
Nilsson NJ. Principles of Artificial Intelligence. Burlington, MA: Morgan Kaufmann (2014).
Greenblatt W, Gupta C, Kao J. Drug repurposing during the COVID-19 Pandemic: Lessons for Expediting Drug Development and access. Health Affairs 2023; 42(3). https://doi.org/10.1377/hlthaff.2022.01083
Pires C. A Systematic Review on the Contribution of Artificial Intelligence in the Development of Medicines for COVID-2019. J Pers Med. 2021 Sep 18;11(9):926. doi: 10.3390/jpm11090926
Ghosh R, Sudheer KT, Kamaraj R. Artificial intelligence (AI) in regulatory approval process. IJBPAS 2024; 13(9):4388-4396
Zhou Y, Wang F, Tang J, et al. Artificial intelligence in COVID-19 drug repurposing. Lancet Digit Health. 2020 Dec;2(12):e667-e676. doi: 10.1016/S2589-7500(20)30192-8
Ke YY, Peng TT, Yeh TK, et al. Artificial intelligence approach fighting COVID-19 with repurposing drugs. Biomed J. 2020 Aug;43(4):355-362. doi: 10.1016/j.bj.2020.05.001
Mohanty S, Harun Ai Rashid M, et al. Application of Artificial Intelligence in COVID-19 drug repurposing. Diabetes Metab Syndr. 2020 Sep-Oct;14(5):1027-1031. doi: 10.1016/j.dsx.2020.06.068.
Gao K, Nguyen DD, Chen J, et al. Repositioning of 8565 Existing Drugs for COVID-19. J Phys Chem Lett. 2020 Jul 2;11(13):5373-5382. doi: 10.1021/acs.jpclett.0c01579
Beck BR, Shin B, Choi Y, et al. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020 Mar 30;18:784790. doi: 10.1016/j.csbj.2020.03.025
Acharya A, Agarwal R, Baker MB, et al. Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19. J Chem Inf Model. 2020 Dec 28;60(12):58325852. doi: 10.1021/acs.jcim.0c01010
Unni S, Aouti S, Thiyagarajan S, et al. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods. J Biosci. 2020;45(1):130. doi: 10.1007/s12038-020-00102-w
Zeng X, Song X, Ma T, et al. Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning. J Proteome Res. 2020 Nov 6;19(11):4624-4636. doi: 10.1021/acs.jproteome.0c00316
Kaushik A, Raj U. AI-driven drug discovery: A boon against COVID-19? AI Open 2020; 1:1-4. Doi:https://doi.org/10.1016/j.aiopen.2020.07.001
Asselah T, Durantel D, Pasmant E, et al. COVID-19: Discovery, diagnostics and drug development. J Hepatol. 2021 Jan;74(1):168-184. doi: 10.1016/j.jhep.2020.09.031
Mottaqi M, Mohammadipanah F, Sajedi H. Contribution of machine learning approached in response to SARS-CoV-2 infection. Informatics in Medicine Unlocked 2021; 23:100526. https://doi.org/10.1016/j.imu.2021.10052
Prasad K, Kumar V. Artificial intelligence-driven drug repurposing and structural biology for SARS-CoV-2. Current research in pharmacology and drug discovery 2021; 2: 100042
Smith DP, Oechsie O, Rawling MJ et al. Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19. Front. Pharmacol 2021; 12. Doi: Volume 12 – 2021, https://doi.org/10.3389/fphar.2021.709856
Djokovic N, Ruzic D, Djikic T, et al. An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main Protease. Mol Inform. 2021 May;40(5):e2000187. doi: 10.1002/minf.202000187
Behera SK, Mahapatra NT, Chandra S, et al. Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach. Indian Journal of Medical Research. 2021; 153(1-2):p 132-143, doi: 10.4103/ijmr.IJMR_1132_20
Rajput A, Thakur A, Mukhopadhyay A, et al. Prediction of repurposed drugs for Coronaviruses using artificial intelligence and machine learning. Comput Struct Biotechnol J. 2021;19:3133-3148. doi: 10.1016/j.csbj.2021.05.037
Sibilio P, Bini S, Fiscon G et al. In silico drug repurposing in COVID-19: A network-based analysis. Biomedicine & Pharmacotherapy 2021; 142, 111954. doi:https://doi.org/10.1016/j.biopha.2021.111954
Haneczok J, Delijewski M. Machine learning enabled identification of potential SARS-CoV-2 3CLpro inhibitors based on fixed molecular fingerprints and Graph-CNN neural representations. Journal of Biomedical Informatics 2021; 19:103821. https://doi.org/10.1016/j.jbi.2021.103821
El-Hddad S, Sobhy M, Ayoub A, et al. In silico molecular docking, dynamics simulation and repurposing of some VEGFR-2 inhibitors based on the SARS-CoV-2-main-protease inhibitor N3. J Biomol Struct Dyn. 2023 Nov;41(19):9267-9281. doi: 10.1080/07391102.2022.2148000
Cong Y, Endo T. Multi-Omics and Artificial Intelligence-Guided Drug Repositioning: Prospects, Challenges, and Lessons Learned from COVID-19 (OMICS (2022) 26:7(361-371) doi: 10.1089/omi.2022.0068)
Ozdemir ES, Ranganathan SV, Nussinov R. How has artificial intelligence impacted COVID-19 drug repurposing and what lessons have we learned? Expert Opinion on Drug Discovery, 2022;17(10), 1061–1065. https://doi.org/10.1080/17460441.2022.2128333
Liu Z, Chen X, Carter W, Moruf A, et al. AI-powered drug repurposing for developing COVID-19 treatments. Reference Module in Biomedical Sciences. 2022:B978-0-12-8240106.00005-8. doi: 0.1016/B978-0-12-824010-6.00005-8
Hu F, Jiang J, Yin P. Prediction of Potential Commercially Available Inhibitors against SARS-CoV-2 by Multi-Task Deep Learning Model. Biomolecules. 2022 Aug 21;12(8):1156. doi: 10.3390/biom12081156
Pires C. A Systematic Review on the Contribution of Artificial Intelligence in the Development of Medicines for COVID-2019. J Pers Med. 2021 Sep 18;11(9):926. doi: 10.3390/jpm11090926
MacMahon M, Hwang W, Yim S, et al. An in silico drug repurposing pipeline to identify drugs with the potential to inhibit SARS-CoV-2 replication. arXiv; 2022.
Singh A. Artificial intelligence for drug repurposing against diseases. Artificial Intelligence Chemistry 2024; 2(2), 100071. doi: https://doi.org/10.1016/j.aichem.2024.100071
Kokic G, Hillen HS, Tegunov D, et al. Mechanism of SARSCoV-2 polymerase stalling by remdesivir. Nat Commun 12, 279 (2021). https://doi.org/10.1038/s41467-020-20542-0
Tchesnokov EP, Feng JY, Porter DP, et al. Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses. 2019 Apr 4;11(4):326. doi: 10.3390/v11040326
Choudhury C, Arul Murugan N, Priyakumar UD. Structure-based drug repurposing: Traditional and advanced AI/ML-aided methods. Drug Discov Today. 2022 Jul;27(7):1847-1861. doi: 10.1016/j.drudis.2022.03.006.
Richardson P, Griffin I, Tucker C, et al. Baricitinib as a potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020; 395: e30-e31
Santoro MG, Carafoli E. Remdesivir: From Ebola to COVID-19. Biochem Biophys Res Commun. 2021 Jan 29;538:145150. doi: 10.1016/j.bbrc.2020.11.043
Scott RE, Mars M. Principles and framework for eHealth strategy development. J Med Internet Res. 2013 Jul 30;15(7):e155. doi: 10.2196/jmir.2250
Sarker R, Roknuzzaman ASM, Hossain MJ, et al. The WHO declares COVID-19 is no longer a public health emergency of international concern: benefits, challenges, and necessary precautions to come back to normal life. Int J Surg. 2023 Sep 1;109(9):2851-2852. doi: 10.1097/JS9.0000000000000513
Sawan R, Adrija M, Chirantan C. Did the COVID-19 pandemic propel usage of AI in pharmaceutical innovation? New evidence from patenting data,Technological Forecasting and Social Change, Volume 198, 2024, 122940, ISSN 0040-1625, https://doi.org/10.1016/j.techfore.2023.122940.
He B, Garmire L. Prediction of repurposed drugs for treating lung injury in COVID-19. ArXiv [Preprint]. 2020 Mar 30:arXiv:2003.14333v2. Update in: F1000Res. 2020 Jun 15;9:609. doi: 10.12688/f1000research.23996.1
Anuradha S. Artificial intelligence for drug repurposing against infectious diseases, Artificial Intelligence Chemistry, Volume 2, Issue 2, 2024, 100071, ISSN 2949-7477, https://doi.org/10.1016/j.aichem.2024.100071.
Gonin- Qualikene W, Jaulent M, Thierry J, et al. Artificial intelligence integration in the drug lifecycle and in regulatory science: policy implications, challenges and opportunities. Front. Pharmacol, 2024, Volume 15 – 2024 | https://doi.org/10.3389/fphar.2024.1437167
Eastman RT, Roth JS, Brimacombe KR, et al. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent Sci. 2020 May 27;6(5):672-683. doi: 10.1021/acscentsci.0c00489. Erratum in: ACS Cent Sci. 2020 Jun 24;6(6):1009. doi: 10.1021/acscentsci.0c00747
Herráiz-Gil S, Nygren-Jiménez E, Acosta-Alonso DN, et al. S. Artificial Intelligence-Based Methods for Drug Repurposing and Development in Cancer. Appl. Sci. 2025, 15, 2798. https://doi.org/10.3390/app15052798
Cortial L, Montero V, Tourlet S, et al. Artificial intelligence in drug repurposing for rare diseases: a mini-review. ront. Med. 2024; 11:1404338. doi: 10.3389/fmed.2024.1404338
Muratov E, Amaro R, Andrade C, et al. A critical overview of computational approaches employed for COVID-19 drug discovery. Chemical Society Reviews 2021; 50, 9121-9151. https://doi.org/10.1039/D0CS01065K
Chenrui L, Wenqiang G, Xinyi Y, et al. Innovative applications of artificial intelligence during the COVID-19 pandemic, Infectious Medicine, Volume 3, Issue 1, 2024, 100095, ISSN 2772431X, https://doi.org/10.1016/j.imj.2024.100095.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 M. Dimitrova, R. Trifonova, G. Stavrakov, I. Doytchinova, G. Petrova (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
